Article ID Journal Published Year Pages File Type
5701424 Journal of Thoracic Oncology 2017 25 Pages PDF
Abstract
First-line afatinib appears cost-effective compared with gefitinib for patients with EGFR mutation-positive NSCLCs.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers
Authors
, , , , , , , , , , , , , , ,